Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.941.07%
QQQ
716.831.15%
BTC/USD
77121.630.7674%
DIA
526.651.13%
GLD
399.930.9%
TLT
81.000.27%

Marker Therapeutics Inc

MRKRNASDAQ
Trade with Public
Trade with Public
$1.28
0.086.67%
Last update: Sep 8, 4:02 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Marker Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Marker Therapeutics (MRKR).

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

1S.Buy
3Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$12Upside to Avg. PT+867.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Dec 8, 2025HC Wainwright & Co.Patrick R. TrucchioInitiateBuy$10
Apr 1, 2025WBB SecuritiesSteve BrozakMaintainedStrong Buy$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $10.
Benzinga Newsdesk

PRO
WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target

WBB Securities analyst Steve Brozak reiterates Marker Therapeutics (NASDAQ:MRKR) with a Strong Buy and maintains $12.5 price target.
Benzinga Newsdesk

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

PRO
Canaccord Genuity Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $8

Canaccord Genuity analyst John Newman initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
Ladenburg Thalmann Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $11

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy t
Vandana Singh

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved